Shilpa Medicare Limited receives WHO-Geneva approval for API, Tenofovir Disoproxil Fumarate

Shilpa Medicare Limited (SHILPAMED) today announced the receipt of confirmation of WHO - GENEVA approval for API, Tenofovir Disoproxil Fumarate, a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS, under pre-qualification program.

Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs. 630.3 as compared to the previous close of Rs. 623.6. The total number of shares traded during the day was 84396 in over 3342 trades.

The stock hit an intraday high of Rs. 642.9 and intraday low of 606.05. The net turnover during the day was Rs. 52660272.

Source : Equity Bulls

Keywords